Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
Significant overall survival benefit seen for Glofit-GemOx at primary and follow-up analysis
Acupuncture Reduces Endocrine Symptoms, Hot Flashes in Breast Cancer
Significant improvement seen in endocrine symptom subscale score, hot flash score, FACT-Breast total score
Nonsignificant Survival Benefit Seen for Dabrafenib, Trametinib in Melanoma
Consistent survival benefit seen across several prespecified subgroups, including those with a BRAF V600E mutation
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
PTCy GVHD prophylaxis after allogeneic stem cell transplant yields comparable relapse incidence, lower GVHD
Improved Outcomes Seen With Ibrutinib in Chronic Lymphocytic Leukemia
Time to next treatment was improved for first-line ibrutinib versus chemoimmunotherapy in match-adjusted analyses
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
Significant reductions in disease progression or death seen with both mismatch repair-proficient and -deficient cases
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is Low
Increase in UTD-LCS prevalence seen with age and number of comorbidities; relatively lower levels seen in Southern states
Surveillance IDs New Tumors in Children With Cancer Predisposition
Standardized surveillance of children with cancer predisposition syndromes has high sensitivity, specificity, PPV, NPV
Study Quantifies Risk for Gastric, Breast Cancer for Germline CDH1 P/LP Variants
Lifetime cumulative risk for advanced gastric cancer 10.3 and 6.5 percent for male and female carriers, respectively
FDA Approves Augtyro for NTRK-Positive Advanced Solid Tumors
Approval is for both TKI-naive and TKI-pretreated patients across solid tumor types
